The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ny, Lars, Jespersen, Henrik, Karlsson, Joakim, Alsén, Samuel, Filges, Stefan, All-Eriksson, Charlotta, Andersson, Bengt, Carneiro, Ana, Helgadottir, Hildur, Levin, Max, Ljuslinder, Ingrid, Olofsson Bagge, Roger, Sah, Vasu R., Stierner, Ulrika, Ståhlberg, Anders, Ullenhag, Gustav, Nilsson, Lisa M., Nilsson, Jonas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397717/
https://www.ncbi.nlm.nih.gov/pubmed/34453044
http://dx.doi.org/10.1038/s41467-021-25332-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397717/
https://www.ncbi.nlm.nih.gov/pubmed/34453044
http://dx.doi.org/10.1038/s41467-021-25332-w

Ejemplares similares